Drug Retention Rates and the Safety of Janus Kinase Inhibitors in Elderly Patients with Rheumatoid Arthritis.

Jumpei TemmokuMasayuki MiyataEiji SuzukiYuya SumichikaKenji SaitoShuhei YoshidaHaruki MatsumotoYuya FujitaNaoki MatsuokaTomoyuki AsanoShuzo SatoKiyoshi Migita

Published in: Journal of clinical medicine (2023)

Our results suggest that the overall drug retention rate of JAKis in very elderly patients (≥75 years) was comparable with that in elderly patients (65 ≤ years < 75). The discontinuation rates of JAKis due to AEs were also comparable both in very elderly group patients and elderly patients.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
community dwelling
prognostic factors
peritoneal dialysis
adverse drug
patient reported